Journal profile · Pharmacology & Pharmacy
Chemotherapy
ISSN 0009-3157 · eISSN 1421-9794 · S. Karger AG · SWITZERLAND · Bimonthly · Founded 1968
Chemotherapy: CAS Zone 4 · Medicine (2025 upgraded edition); impact factor 1.28; hybrid open access; median 67 days to acceptance (24 articles, last 24 months); community-reported acceptance: fairly easy; 10 articles in 2025; indexed in SCIE and Scopus.
Scope
Aims, scope and focus
Chemotherapy is published by S. Karger AG and is in Zone 4 of Medicine in the CAS Journal Ranking (2025 upgraded edition). By OpenAlex counts of its recent articles, its largest topics are Legal and Regulatory Analysis, Linguistic, Cultural, and Literary Studies and Military Technology and Strategies, together about 55.8% of its articles. (generated from OpenAlex topic counts and CAS ranking data)
Chemotherapy publishes original research articles and state-of-the-art reviews on all aspects of antimicrobial and antitumor chemotherapy. The results of experimental and clinical investigations into the microbiological and pharmacological properties of antibacterial, antiviral, and antitumor compounds are major topics of publication. Papers selected for the journal offer data concerning the efficacy, toxicology, and interactions of new drugs in single or combined applications. Studies designed to determine the pharmacokinetic and pharmacodynamic properties of similar preparations and comparing their efficacy are also included. Special emphasis is given to the development of drug resistance, an increasing problem worldwide.
From the journal's Aims & Scope
Research area (LetPub): Pharmacology & Pharmacy
Editor-in-chief Giorgio MinottiPublisher website
Main research topics OpenAlex counts of recent articles; shares are approximate
- Legal and Regulatory AnalysisSocial Sciences18.6%
- Linguistic, Cultural, and Literary StudiesSocial Sciences18.6%
- Military Technology and StrategiesEngineering18.6%
- Antibiotics Pharmacokinetics and EfficacyMedicine10.2%
- Antibiotic Resistance in BacteriaBiochemistry, Genetics and Molecular Biology5.6%
- Antimicrobial Resistance in StaphylococcusMedicine3%
- Drug-Induced Adverse ReactionsMedicine2.9%
- Pneumonia and Respiratory InfectionsMedicine2.7%
Rankings & indexing
CAS ranking and database indexing
CAS Journal Ranking
CAS Journal Ranking, upgraded edition (March 2025)Medicine Zone 4
| Level | Category | Zone |
|---|---|---|
| Major | Medicine | Zone 4 |
| Minor | Oncology | Zone 4 |
| Minor | Pharmacology & Pharmacy | Zone 4 |
Top journal: noReview journal: no
CAS Xinrui Journal Ranking (March 2026)Medicine Zone 4
| Level | Category | Zone |
|---|---|---|
| Major | Medicine | Zone 4 |
| Minor | Oncology | Zone 4 |
| Minor | Pharmacology & Pharmacy | Zone 4 |
Top journal: noReview journal: not marked
CAS Journal Ranking, previous upgraded edition (December 2023)Medicine Zone 4
| Level | Category | Zone |
|---|---|---|
| Major | Medicine | Zone 4 |
| Minor | Oncology | Zone 4 |
| Minor | Pharmacology & Pharmacy | Zone 4 |
Top journal: noReview journal: no
Database indexing
SCIEScopusLetPub
International journal early-warning lists: not listed in any editionLetPub
Editions, and major and minor categories, are shown separately and never merged into one zone; check which edition your institution uses before you submit or report.
Metrics
Impact metrics and publication volume
Impact
- Impact factor
- 1.28LetPub ·
- Impact factor (publisher)
- 1.4Publisher website ·
- CiteScore 2026-06
- 3.6LetPub ·
- CiteScore (publisher)
- 3.6Publisher website ·
- SJR 2026-06
- 0.44LetPub ·
- SNIP 2026-06
- 0.51LetPub ·
- h-index
- 49LetPub ·
- h-index
- 80OpenAlex ·
- i10-index
- 1,692OpenAlex ·
- 2-year mean citedness
- 1.82OpenAlex ·
- Self-citation rate
- 0%LetPub ·
- Share of gold OA articles
- 11.11%LetPub ·
Volume
- Articles per year
- 9LetPub ·
Articles by year OpenAlex count · 10,325 in total · the current year is incomplete
| Year | Articles | Open access | Citations |
|---|---|---|---|
| 2026 | 7 | 3 | 0 |
| 2025 | 10 | 4 | 16 |
| 2024 | 28 | 6 | 66 |
| 2023 | 34 | 10 | 101 |
| 2022 | 41 | 8 | 220 |
| 2021 | 47 | 16 | 528 |
Sources count differently and were observed at different times, so each source's own value is kept; "publisher" marks figures from the journal's website.
Review & acceptance
Review time and acceptance
Review time from article dates manuscript dates registered with PubMed · to
67 daysMedian, submission to acceptance · P25–P75 47 days – 99 days
- Acceptance to online
- median 13 days (24 articles)
- Submission to online
- median 83 days
- Sample
- 24 articles with submission and acceptance dates (28 in the window); the latest was accepted on
Only articles that were accepted and published are counted, not the time spent on rejected manuscripts, so this usually runs longer than a publisher's "time to first decision".
Other sources
- Average review time (community reports)
- 6–12 weeksLetPub ·
- Average acceptance (community reports)
- Fairly easyLetPub ·
- Submission to first decision
- 14 daysPublisher website ·
Community reports come from authors' own submissions (confidence 0.5) and are not a promise from the journal; for publisher figures, the journal's own definitions apply.
Fees & open access
APC and open-access policy
Hybrid open accessLetPub
A subscription journal in which authors can pay to publish their article open access.
No source has fee information yet; check the journal's website.
A hybrid journal charges the APC only when the author chooses open access; publishing under the subscription model is usually free.
The journal's website is authoritative for fees; sources were observed at different times and each keeps its own value, without averaging.
Profile
Publication details and official links
- Publisher
- S. Karger AG
- Country or region
- SWITZERLAND
- Language
- English
- Frequency
- Bimonthly
- Founded
- 1968
- ISSN
- 0009-3157
- Electronic ISSN
- 1421-9794
- Latest issue on the website
- Volume 71, Issue 1 (2026)
- Official links
- Journal homepage ↗LetPub
- Submission system ↗Publisher website
- Special issues ↗Publisher website
FAQ
Frequently asked questions about Chemotherapy
What CAS zone is Chemotherapy in?
In the 2025 upgraded edition of the CAS Journal Ranking, Chemotherapy is in Zone 4 of Medicine, and in Zone 4 of the minor category Oncology / Pharmacology & Pharmacy. In the 2026 Xinrui edition it is in Zone 4 of Medicine. Zones from different editions, and from major and minor categories, are not interchangeable.
What is the impact factor of Chemotherapy?
The latest impact factor listed by LetPub is 1.28; CiteScore 3.6, h-index 80.
How long does peer review take at Chemotherapy?
Based on the dates recorded on 24 articles published between October 2024 and October 2026 (the last 24 months), the median time from submission to acceptance is 67 days (interquartile range 47–99 days); authors report an average review time of 6–12 weeks; the community-reported acceptance is “Fairly easy”. Article statistics cover accepted papers only, publisher figures follow the journal's own definitions, and community reports come from authors' own submissions; none is a promise from the journal.
Which databases index Chemotherapy?
According to LetPub and DOAJ records, Chemotherapy is indexed in SCIE and Scopus.
Is Chemotherapy open access, and what is the APC?
Chemotherapy is a hybrid journal. Fee information is not available yet; check the journal's website.
Sources and updates
The facts on this page come from LetPub, OpenAlex, Publisher website; every figure is tagged with its source and the date it was observed, and conflicting values are kept per source. LetPub source page: view ↗ (archived 2026-08-25). Last updated: .